NO315647B1 - Sulfonyl divalente aryl eller heteroaryl hydroksamsyreforbindelser, anvendelse av samme for fremstilling av et medikament samt farmasöytisksammensetning innbefattende samme - Google Patents

Sulfonyl divalente aryl eller heteroaryl hydroksamsyreforbindelser, anvendelse av samme for fremstilling av et medikament samt farmasöytisksammensetning innbefattende samme

Info

Publication number: NO315647B1
Authority: NO; Norway
Prior art keywords: same; hydroxamic acid; medicament; preparation; pharmaceutical composition
Prior art date: 1997-03-04

Application number

NO19994252A

Other languages

English (en)

Other versions

NO994252L (no

NO994252D0 (no

Inventor

Joseph J Mcdonald

Thomas E Barta

Daniel P Becker

Louis J Bedell

Shashidhar N Rao

John N Freskos

Brent V Mischke

Original Assignee

Monsanto Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-04

Filing date

1999-09-02

Publication date

2003-10-06

1999-09-02 Application filed by Monsanto Co filed Critical Monsanto Co

1999-09-02 Publication of NO994252L publication Critical patent/NO994252L/no

1999-09-02 Publication of NO994252D0 publication Critical patent/NO994252D0/no

2003-10-06 Publication of NO315647B1 publication Critical patent/NO315647B1/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

NO19994252A 1997-03-04 1999-09-02 Sulfonyl divalente aryl eller heteroaryl hydroksamsyreforbindelser, anvendelse av samme for fremstilling av et medikament samt farmasöytisksammensetning innbefattende samme NO315647B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3518297P	1997-03-04	1997-03-04
PCT/US1998/004300 WO1998038859A1 (en)	1997-03-04	1998-03-04	Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds

Publications (3)

Publication Number	Publication Date
NO994252L NO994252L (no)	1999-09-02
NO994252D0 NO994252D0 (no)	1999-09-02
NO315647B1 true NO315647B1 (no)	2003-10-06

Family

ID=21881145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994252A NO315647B1 (no)	1997-03-04	1999-09-02	Sulfonyl divalente aryl eller heteroaryl hydroksamsyreforbindelser, anvendelse av samme for fremstilling av et medikament samt farmasöytisksammensetning innbefattende samme

Country Status (20)

Country	Link
US (3)	US6380258B2 (no)
EP (4)	EP0983257A4 (no)
JP (4)	JP2002515901A (no)
KR (3)	KR20000075954A (no)
CN (3)	CN1254337A (no)
AT (1)	ATE254599T1 (no)
AU (2)	AU750130B2 (no)
BR (2)	BR9808166A (no)
CA (4)	CA2283272A1 (no)
DE (1)	DE69819878T2 (no)
DK (1)	DK0973392T3 (no)
EA (1)	EA199900792A1 (no)
ES (2)	ES2209122T3 (no)
HK (1)	HK1027806A1 (no)
IL (3)	IL131493A (no)
NO (1)	NO315647B1 (no)
NZ (1)	NZ337326A (no)
PL (1)	PL335732A1 (no)
PT (1)	PT973392E (no)
WO (1)	WO1998038859A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6747027B1 (en)	1996-07-22	2004-06-08	Pharmacia Corporation	Thiol sulfonamide metalloprotease inhibitors
US6794511B2 (en)	1997-03-04	2004-09-21	G. D. Searle	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en)	1997-03-04	2004-02-24	Pharmacia Corporation	Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
JP2002515901A (ja)	1997-03-04	2002-05-28	モンサントカンパニー	芳香族スルホニルα−シクロアミノヒドロキサム酸化合物
NZ503997A (en) *	1997-11-21	2001-09-28	Upjohn Co	Alpha-hydroxy, -amino, or halo derivatives of beta-sulfonyl hydroxamic acids useful as matrix metalloproteinases inhibitors
WO2000037433A1 (en) *	1998-12-18	2000-06-29	Abbott Laboratories	Inhibitors of matrix metalloproteinases
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
US6465468B1 (en)	1999-03-22	2002-10-15	Darwin Discovery Limited	Hydroxamic and carboxylic acid derivatives
KR20020009610A (ko) *	1999-05-12	2002-02-01	윌리암스 로저 에이	매트릭스 메탈로프로테아제 억제제로서의 히드록삼산 유도체
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1233958B1 (en)	1999-11-23	2011-06-29	MethylGene Inc.	Inhibitors of histone deacetylase
WO2002030879A2 (en)	2000-09-29	2002-04-18	Prolifix Limited	Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
EP1598067B1 (en)	2000-09-29	2009-05-06	TopoTarget UK Limited	Carbamic acid compounds comprising an amide linkage for the treatment of malaria
SG173211A1 (en)	2001-06-26	2011-08-29	Amgen Inc	Antibodies to opgl
US6683078B2 (en) *	2001-07-19	2004-01-27	Pharmacia Corporation	Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
EP1492534B1 (en) *	2002-04-03	2008-06-25	TopoTarget UK Limited	Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
CA2483314A1 (en)	2002-04-25	2003-11-06	Pharmacia Corporation	Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0226855D0 (en) *	2002-11-18	2002-12-24	Queen Mary & Westfield College	Histone deacetylase inhibitors
DE60331367D1 (de)	2002-12-30	2010-04-01	Angiotech Int Ag	Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
ES2537514T3 (es)	2003-04-04	2015-06-09	Incyte Corporation	Composiciones, métodos y kits relacionados con la escisión de HER-2
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
PL1735274T3 (pl) *	2004-03-22	2010-05-31	Southern Res Inst	Niepeptydowe inhibitory metaloproteinaz macierzy zewnątrzkomórkowej
WO2005117882A2 (en) *	2004-04-20	2005-12-15	Incyte Corporation	Hydroxamic acid derivatives as metalloprotease inhibitors
WO2006004598A2 (en) *	2004-06-01	2006-01-12	The Scripps Research Institute	Proteomic analysis
US20050277897A1 (en) *	2004-06-14	2005-12-15	Ghannoum Ziad R	Handpiece tip
TW200700392A (en) *	2005-03-16	2007-01-01	Astrazeneca Ab	Novel compounds
CN101273013B (zh) *	2005-09-27	2013-06-12	盐野义制药株式会社	具有pgd2受体拮抗活性的磺酰胺衍生物
AU2009310952B2 (en) *	2008-10-27	2015-04-30	Mitsubishi Tanabe Pharma Corporation	Novel amide derivative and use thereof as medicine
CN102639494B (zh)	2009-10-09	2016-11-09	扎夫根公司	砜化合物及其制备和使用方法
EP2595988B1 (en)	2010-07-22	2014-12-17	Zafgen, Inc.	Tricyclic compounds and methds of making and using same
US9321740B2 (en)	2011-01-26	2016-04-26	Zafgen, Inc.	Tetrazole compounds and methods of making and using same
US9187494B2 (en)	2011-05-06	2015-11-17	Zafgen, Inc.	Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
JP6035327B2 (ja)	2011-05-06	2016-11-30	ザフゲン，インコーポレイテッド	三環式ピラゾールスルホンアミド化合物ならびにその製造および使用方法
BR112013028534A2 (pt)	2011-05-06	2016-09-06	Zafgen Inc	compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
CN104892457B (zh) *	2011-07-25	2017-07-28	中国医学科学院医药生物技术研究所	一种异羟肟酸类衍生物、其药物组合物、制备方法及用途
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
MX2014008706A (es)	2012-01-18	2015-03-05	Zafgen Inc	Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
EP2804856B1 (en)	2012-01-18	2017-03-15	Zafgen, Inc.	Tricyclic sulfone compounds and methods of making and using same
KR20150080614A (ko)	2012-11-05	2015-07-09	자프겐 인크.	비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
CA2890342A1 (en)	2012-11-05	2014-05-08	Zafgen, Inc.	Tricyclic compounds and methods of making and using same
WO2014071368A1 (en)	2012-11-05	2014-05-08	Zafgen, Inc.	Methods of treating liver diseases
BR112015009710A2 (pt) *	2012-11-09	2017-07-04	Unilever Nv	composição para tratamento de um substrato, métodos de tratamento de um substrato e para preparação da composição e agente condicionador
TW201625620A (zh) *	2014-05-14	2016-07-16	美國科羅拉多州立大學	作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
WO2020006384A1 (en) *	2018-06-29	2020-01-02	Loyola University Of Chicago	Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy
CN111217722B (zh) *	2020-03-06	2024-01-02	华东理工大学	偶氮芳基脲类衍生物及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4148801A (en)	1978-07-03	1979-04-10	American Home Products Corporation	3-[(Chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid derivatives
US4595700A (en)	1984-12-21	1986-06-17	G. D. Searle & Co.	Thiol based collagenase inhibitors
US5103014A (en)	1987-09-30	1992-04-07	American Home Products Corporation	Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
GB2212153B (en)	1987-11-16	1992-01-15	Squibb & Sons Inc	Phenyl hydroxamic acids
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5527945A (en) *	1989-02-10	1996-06-18	Basf Aktiengesellschaft	Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
DK0493925T3 (da) *	1990-12-17	1998-07-27	Sankyo Co	Pyrazolderivater med herbicid aktivitet, deres fremstilling og anvendelse
ATE150452T1 (de) *	1992-04-07	1997-04-15	British Biotech Pharm	Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
US5376664A (en)	1992-07-27	1994-12-27	The Du Pont Merck Pharmaceutical Company	Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
US5646167A (en)	1993-01-06	1997-07-08	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamix acids
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5552419A (en)	1993-01-06	1996-09-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en)	1993-04-17	1993-06-02	Walls Alan J	Hydroxamic acid derivatives
GB9320660D0 (en) *	1993-10-07	1993-11-24	British Bio Technology	Inhibition of cytokine production
GB9323165D0 (en)	1993-11-10	1994-01-05	Chiros Ltd	Compounds
AU2394795A (en)	1994-04-28	1995-11-29	Du Pont Merck Pharmaceutical Company, The	Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en)	1994-08-20	1994-10-12	British Biotech Pharm	Metalloproteinase inhibitors
CA2201639A1 (en)	1994-10-05	1996-04-18	John Montana	Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5789434A (en) *	1994-11-15	1998-08-04	Bayer Corporation	Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TR199800990T2 (xx)	1995-12-08	1998-07-21	Agouron Pharmaceuticals, Inc.	Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.
ATE225343T1 (de)	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren
WO1997024117A1 (en) *	1996-01-02	1997-07-10	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
KR20000022532A (ko)	1996-06-27	2000-04-25	오노 야꾸힝 고교 가부시키가이샤	아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
DE69729007T2 (de) *	1996-08-07	2005-04-07	Darwin Discovery Ltd., Slough	Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
PL332509A1 (en) *	1996-09-27	1999-09-13	Upjohn Co	Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
DE69801530T2 (de) *	1997-01-13	2002-05-08	Fuji Photo Film Co Ltd	Wärmeentwickelbares, photoempfindliches Farbmaterial
CA2279863A1 (en) *	1997-02-07	1998-08-13	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
GEP20022627B (en) *	1997-02-27	2002-02-25	American Cyanamid Company Us	N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors
JP2002515901A (ja)	1997-03-04	2002-05-28	モンサントカンパニー	芳香族スルホニルα−シクロアミノヒドロキサム酸化合物
US20010014688A1 (en) *	1997-11-14	2001-08-16	Thomas E. Barta	Aromatic sulfone hydroxamic acid metalloprotease inhibitor

1998
- 1998-03-04 JP JP53878098A patent/JP2002515901A/ja not_active Abandoned
- 1998-03-04 KR KR1019997008036A patent/KR20000075954A/ko not_active Application Discontinuation
- 1998-03-04 CN CN98804628A patent/CN1254337A/zh active Pending
- 1998-03-04 WO PCT/US1998/004300 patent/WO1998038859A1/en not_active Application Discontinuation
- 1998-03-04 PT PT98911481T patent/PT973392E/pt unknown
- 1998-03-04 CA CA002283272A patent/CA2283272A1/en not_active Abandoned
- 1998-03-04 PL PL98335732A patent/PL335732A1/xx unknown
- 1998-03-04 CA CA002283275A patent/CA2283275A1/en not_active Abandoned
- 1998-03-04 ES ES98910177T patent/ES2209122T3/es not_active Expired - Lifetime
- 1998-03-04 JP JP53879998A patent/JP2001518081A/ja not_active Abandoned
- 1998-03-04 IL IL13149398A patent/IL131493A/en not_active IP Right Cessation
- 1998-03-04 EP EP98908949A patent/EP0983257A4/en not_active Withdrawn
- 1998-03-04 BR BR9808166-7A patent/BR9808166A/pt not_active Application Discontinuation
- 1998-03-04 JP JP53798598A patent/JP2002515900A/ja not_active Abandoned
- 1998-03-04 CN CN98804575A patent/CN1105114C/zh not_active Expired - Fee Related
- 1998-03-04 ES ES98911481T patent/ES2206903T3/es not_active Expired - Lifetime
- 1998-03-04 US US09/230,209 patent/US6380258B2/en not_active Expired - Fee Related
- 1998-03-04 EP EP98910177A patent/EP0984959B1/en not_active Expired - Lifetime
- 1998-03-04 CA CA002282318A patent/CA2282318A1/en not_active Abandoned
- 1998-03-04 AU AU65424/98A patent/AU750130B2/en not_active Ceased
- 1998-03-04 IL IL13149598A patent/IL131495A0/xx unknown
- 1998-03-04 EP EP98908964A patent/EP0983258A4/en not_active Withdrawn
- 1998-03-04 NZ NZ337326A patent/NZ337326A/en unknown
- 1998-03-04 AT AT98911481T patent/ATE254599T1/de not_active IP Right Cessation
- 1998-03-04 KR KR1019997008028A patent/KR20000075946A/ko not_active Application Discontinuation
- 1998-03-04 DK DK98911481T patent/DK0973392T3/da active
- 1998-03-04 IL IL13149498A patent/IL131494A/xx not_active IP Right Cessation
- 1998-03-04 KR KR1019997008037A patent/KR20000075955A/ko not_active Application Discontinuation
- 1998-03-04 CN CN98804577A patent/CN1253474A/zh active Pending
- 1998-03-04 EP EP98911481A patent/EP0973392B1/en not_active Expired - Lifetime
- 1998-03-04 JP JP53879698A patent/JP2002513407A/ja not_active Abandoned
- 1998-03-04 DE DE69819878T patent/DE69819878T2/de not_active Expired - Fee Related
- 1998-03-04 BR BR9808214-0A patent/BR9808214A/pt not_active IP Right Cessation
- 1998-03-04 AU AU66865/98A patent/AU750303B2/en not_active Ceased
- 1998-03-04 CA CA002283145A patent/CA2283145A1/en not_active Abandoned
- 1998-03-04 EA EA199900792A patent/EA199900792A1/ru unknown
1999
- 1999-09-02 NO NO19994252A patent/NO315647B1/no unknown
2000
- 2000-11-02 HK HK00106978A patent/HK1027806A1/xx not_active IP Right Cessation
2001
- 2001-11-29 US US09/997,552 patent/US6656954B2/en not_active Expired - Fee Related
2003
- 2003-10-27 US US10/695,278 patent/US20040097487A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR9808214A (pt)	2000-05-16
NZ337326A (en)	2001-05-25
DK0973392T3 (da)	2004-03-29
DE69819878T2 (de)	2004-04-22
EP0983257A4 (en)	2001-05-02
EP0973392A1 (en)	2000-01-26
DE69819878D1 (de)	2003-12-24
CA2283275A1 (en)	1998-09-11
NO994252L (no)	1999-09-02
EP0984959A4 (en)	2001-05-02
IL131493A (en)	2004-05-12
AU6686598A (en)	1998-09-22
EP0984959A1 (en)	2000-03-15
IL131494A0 (en)	2001-01-28
CA2283272A1 (en)	1998-09-11
CN1253474A (zh)	2000-05-17
ES2206903T3 (es)	2004-05-16
AU6542498A (en)	1998-09-22
US20010020021A1 (en)	2001-09-06
CA2283145A1 (en)	1998-09-11
CA2282318A1 (en)	1998-09-11
PT973392E (pt)	2004-04-30
US6380258B2 (en)	2002-04-30
IL131493A0 (en)	2001-01-28
AU6447898A (en)	1998-09-22
EP0984959B1 (en)	2003-09-24
EP0973392B1 (en)	2003-11-19
KR20000075954A (ko)	2000-12-26
JP2002513407A (ja)	2002-05-08
KR20000075946A (ko)	2000-12-26
JP2001518081A (ja)	2001-10-09
ATE254599T1 (de)	2003-12-15
EP0983258A4 (en)	2001-01-17
EP0983258A1 (en)	2000-03-08
IL131495A0 (en)	2001-01-28
CN1253559A (zh)	2000-05-17
KR20000075955A (ko)	2000-12-26
CN1105114C (zh)	2003-04-09
EP0973392A4 (en)	2001-05-02
JP2002515901A (ja)	2002-05-28
WO1998038859A1 (en)	1998-09-11
BR9808166A (pt)	2000-05-16
AU750130B2 (en)	2002-07-11
ES2209122T3 (es)	2004-06-16
US20020103239A1 (en)	2002-08-01
AU737329B2 (en)	2001-08-16
US6656954B2 (en)	2003-12-02
HK1027806A1 (en)	2001-01-23
EP0983257A1 (en)	2000-03-08
PL335732A1 (en)	2000-05-08
JP2002515900A (ja)	2002-05-28
NO994252D0 (no)	1999-09-02
EA199900792A1 (ru)	2000-04-24
IL131494A (en)	2005-06-19
US20040097487A1 (en)	2004-05-20
CN1254337A (zh)	2000-05-24
AU750303B2 (en)	2002-07-18

Publication	Publication Date	Title
NO315647B1 (no)	2003-10-06	Sulfonyl divalente aryl eller heteroaryl hydroksamsyreforbindelser, anvendelse av samme for fremstilling av et medikament samt farmasöytisksammensetning innbefattende samme
ATE283848T1 (de)	2004-12-15	Thiarylsulfonamid-hydroxamsäurederivate
WO2001085680A3 (en)	2002-03-07	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
NZ515197A (en)	2004-03-26	Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors
AP2001002240A0 (en)	2001-09-30	Sufamato hydroxamic acid metalloprotease inhibitor.
IE862404L (en)	1987-03-10	Hydroxamic acid derivatives
BR9810592A (pt)	2000-09-12	Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
DE69811111D1 (de)	2003-03-06	Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
BR0309546A (pt)	2005-02-15	Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
DK420385D0 (da)	1985-09-17	Antioestrogent laegemiddel til perkutan indgift
DE3679920D1 (de)	1991-08-01	Spiro-3-heteroazolidinverbindungen und ihre salze, ihre herstellung und diese enthaltende pharmazeutische mittel.
ES2194003T3 (es)	2003-11-16	Huperzina a racemica.
DK112287D0 (da)	1987-03-04	Anvendelse af 2-alkoxy-n-(1-azabicyclo-oe2,2,2aaoct-3-yl)-benzamider og -thiobenzamider samt farmaceutisk acceptable syreadditionssalte deraf som laegemidler
BRPI0410654A (pt)	2006-06-20	composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE109006T1 (de)	1994-08-15	Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.
BR9803974A (pt)	2000-05-09	Cromanos substituìdos por sulfonamida, processos para a sua preparação, seu emprego como medicamento e preparados farmacêuticos contendo os mesmos
ATE75399T1 (de)	1992-05-15	Therapeutikum zur behandlung von magengeschwueren.
BR9803739A (pt)	2000-03-21	Compostos substituìdos por sulfonamida, processos para sua preparação, seu uso como medicamento ou diagnóstico, e medicamento que os contém.
DE3687448T2 (de)	1993-06-09	Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten.
NO903956D0 (no)	1990-09-11	Sammensetninger som inneholder thymopentin til topisk behandling av hudsykdommer.